In summary, a consistent picture emerges across countries, different assay types, and age of individuals where circulating levels of ANGI and II are not increased, rather in some reports decreased, in patients with mild and severe COVID-19, while critically ill intensive care patients have elevated levels. The gene discussed is AGT; the disease is COVID-19.